Optimus, Mobile phone

Optimus Pharma on Tuesday received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild and Moderate Covid-19 symptoms.With a severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI. The regulator gave a nod for conducting the trial on mild and moderate patients on May 18 2021.As per the clinical trial, protocols approved, a total of 2500 subjects in both mild and moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of 05 days and the total study duration will be a maximum for 29 days from randomisation, the release said."Optimus is all geared to immediately begin clinical trials on Molnupiravir on COVID-19 patients in India. The clinical trial will let us know the efficacy of this molecule on COVID-19 patients," Chairman & Managing Director - Dr D Srinivas Reddy said.In the previous press release, the company stated that Molnupiravir demonstrated highly promising results in reducing viral load to 0.0% in merely 5 days of treatment duration. Based on completed phase 2 part clinical studies, the proposed dosage is 800mg twice daily which significantly reduces viral culture in infected patients not progressing into ARDS.Optimus Pharma is one of the largest manufacturers of the highly successful SARS-CoV-2 antiviral drug without compromising on quality as is the case with Favipiravir (sold under the brand - FAVICOVID). The company aims to do the same with Molnupiravir to cater to the rising demand for Anti-Viral drugs against SARS-CoV-2 in the Indian market.With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.This story is provided by PNN.will not be responsible in any way for the content of this article. (ANI/PNN)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Pahalgam Terror Attack

Tahawwur Rana

IPL 2025

CM Devendra Fadnavis

Mumbai Local

Weather Update

OptimusFOLLOW

Optimus, Latest News

Entertainment :Steven Caple Jr and his expectations from 'Transformers: Rise of the Beasts'

Mumbai (Maharashtra) [India] June 1 With the new 'Transformers: Rise of the Beasts', the wildly popular 'Transformers' franchise ... ...

Technology :Elon Musk unveils Tesla humanoid robot, may cost $20K

San Francisco, Oct 1 Tesla and SpaceX CEO Elon Musk has showcased a prototype of a humanoid robot ... ...

Technology :Addverb's 'SortIE' bot to help e-commerce platforms dispatch orders efficiently

New Delhi, Aug 26 Leading homegrown robotics company Addverb Technologies on Friday launched its robotic sortation system called ... ...

Technology :Tesla robots will be worth more than car business: Musk

San Francisco, April 21 Tesla CEO Elon Musk has predicted that robots will soon be worth more than ... ...

Business :Optimus announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir conducted in India

Optimus Pharma on Sunday submitted the interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid-19 patients. ...

Business :Drugs manufacturer from Hyderabad on overdrive

Optimus Pharma on Tuesday received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild and Moderate Covid-19 symptoms. ...